Vedana Therapeutics emerged from stealth with a $46M Series A.

Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in 2026 is off to a strong start.

It's important to consider your comfort with risk before diving in.

Including the heart drug developer’s offering, four biotechs in 2026 have raised at least $400 million in IPO proceeds — the ...

By Leila Miller BUENOS AIRES, June 19 (Reuters) - Argentina's government has repealed a regulation that had restricted ...

Biopharma dealmaking is driven by pressure to top up drug pipelines ahead of major patent expirations later this decade.

Welcome to WP Intelligence’s AI & Tech Brief, where we examine the transformative technology of artificial intelligence at ...

As AI transforms biology, longevity startups are attracting investors, advancing toward clinical milestones, and reshaping ...

As the technology transforms scientific discovery, industry players are also grappling with the extent of its real-world use ...

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

This year's BIO Gives Back concert will feature global music superstar Jason Derulo as headliner, while Music Beats Cancer's Breakthrough Artists Initiative will spotlight rising performers whose ...

US lawmakers push Treasury to screen outbound biotech investments in China under the COINS Act. BINSA bill targets ...